Home
Products

Recombinant Proteins
Bioactive Proteins Cytokines and Growth Factors Immune Checkpoint Proteins Enzyme Other Proteins

Antibodies
Primary antibodies Recombinant Monoclonal Antibodies Secondary antibodies Flow Cytometry (FACS) Antibodies Neutralizing Antibodies Isotype Controls Research Grade Biosimilars InVivo Plus InVivo Antibodies XtenNano®Nanobodies Bispecific Antibodies Antibodies against Small Molecules Tag Antibodies Anti-idiotype Antibodies

Assay Kits
ELISA Kits ADA Assay Kits PK Assay Kits Antibody Pairs
Research Area
Featured Products
Support
Information
- BioSpotlight
- Literature Highlights
About Us
Promotion Center

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy

Cancer Cell

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the basis of variable patient responses remains unclear. A longitudinal single-cell RNA sequencing atlas of 441 samples from 241 patients across ten cancer entities maps treatment-associated remodeling of the tumor immune microenvironment (TIME). Four conserved TIME subtypes are defined, and transitions during therapy track response better than the baseline state. A 59-gene signature predicted response and survival.

Related products

Catalog No.	Product Name	Description	Target
HV974011	Recombinant Human CD274/PD-L1/B7-H1 Protein	Recombinant Human CD274/PD-L1/B7-H1 Protein, C-His (HV974011) expressed in Mammalian Cells, spanning Met1-Arg238. Purity: >90% by SDS-PAGE. Highlights ●His-Tagged — N-terminal 6×His tag for IMAC purification. ●Mammalian Expression — Proper folding and native glycosylation. ●High Purity — >90% purity verified by SDS-PAGE.	B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Recombinant Proteins

Antibodies

Assay Kits

Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy